Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIDRISE phase 3 study of STN1013800 for acquired blepharoptosis
NL-OMON59896Phase 3Recruiting
- Sponsor
- Santen Pharmaceutical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of oxymetazoline in acquired blepharoptosis, sponsored by Santen Pharmaceutical. Primary endpoint: Change from baseline in MRD1 on Day 14. Started Dec 2024; status: recruiting.
02
Drugs
oxymetazoline
03
Conditions
acquired blepharoptosis
Beyond the preview
Go deeper on NL-OMON59896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59896.